Health
Investigational Alzheimer’s drug reduces molecular markers of the disease – News-Medical.Net
An investigational Alzheimer’s drug reduced molecular markers of disease and curbed neurodegeneration in the brain, without demonstrating…
An investigational Alzheimer’s drug reduced molecular markers of disease and curbed neurodegeneration in the brain, without demonstrating evidence of cognitive benefit, in a phase 2/3 clinical trial led by researchers at Washington University School of…
Continue Reading
-
Business18 hours agoThis ASX 200 healthcare stock crashed 14% to 4-year low. Here’s what happened
-
Business22 hours agoThis leading broker thinks the CSL share price can climb 40%
-
Business14 hours agoDicker Data rides the AI trend to double digit growth
-
Noosa News15 hours agoBob Katter threatens to punch Nine reporter during ant-immigration press conference